With the recent advances in neoantigen identification,peptide-based cancer vaccines offer substantial potential in the field of immunotherapy.However,rapid clearance,low immunogenicity,and insufficient antigen-present...With the recent advances in neoantigen identification,peptide-based cancer vaccines offer substantial potential in the field of immunotherapy.However,rapid clearance,low immunogenicity,and insufficient antigen-presenting cell(APC)uptake limit the efficacy of peptide-based cancer vaccines.This review explores the barriers hindering vaccine efficiency,highlights recent advancements in synthetic delivery systems,and features strategies for the key delivery steps of lymph node(LN)drainage,APC delivery,cross-presentation strategies,and adjuvant incorporation.This paper also discusses the design of preclinical studies evaluating vaccine efficiency,including vaccine administration routes and murine tumor models.展开更多
基金supported by the U.S.National Institutes of Health,National Cancer Institute Grant R01CA257563.
文摘With the recent advances in neoantigen identification,peptide-based cancer vaccines offer substantial potential in the field of immunotherapy.However,rapid clearance,low immunogenicity,and insufficient antigen-presenting cell(APC)uptake limit the efficacy of peptide-based cancer vaccines.This review explores the barriers hindering vaccine efficiency,highlights recent advancements in synthetic delivery systems,and features strategies for the key delivery steps of lymph node(LN)drainage,APC delivery,cross-presentation strategies,and adjuvant incorporation.This paper also discusses the design of preclinical studies evaluating vaccine efficiency,including vaccine administration routes and murine tumor models.
